+++ 821.149 Pressemeldungen +++ 33.966 Newsrooms +++ 6.000 Medien +++

Roche NimbleGen and Biogemma Develop Enhanced Sequence Capture technology for Wheat and Canola

(PresseBox) (Madison, WI, USA, ) Sequence Capture technology was pioneered by Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) with the initial products focused on human research. Subsequent developments have enabled the technology to be successfully transferred to rice and then adapted to maize. In January 2009, Roche NimbleGen and Biogemma announced their collaboration to develop a NimbleGen Sequence Capture protocol adapted to crops containing more complex genomes including polyploid crops such as wheat and rapeseed (canola). The goal of this partnership was to enhance capture performance on these complex species in order to achieve an enrichment rate that makes downstream sequencing more effective. The new NimbleGen Sequence Capture procedure was implemented and evaluated at Biogemma, and researchers are now well equipped for largescale genomic marker discovery for wheat and rapeseed.

While former capture technologies displayed insufficient performance on complex polyploid genomes, the new NimbleGen Sequence Capture protocol developed by this collaboration has proven to be an efficient, reliable, fast, and costeffective frontend method for targeted resequencing. The combined power of the Roche genomics portfolio was shown by employing the combination of NimbleGen Sequence Capture arrays with the GS FLX Titanium sequencing technology from 454 Life Sciences, a Roche company. Routine use of this complete target enrichment and sequencing solution by researchers at Biogemma has revealed that postcapture sequencing data are reliably comprised of sequences of interest, and that the long reads from the 454 Sequencing System facilitate discovery. Along with these enhancements, Biogemma has devised a downstream bioinformatic pipeline intended for read assembly and to efficiently deal with homeologs and paralogs for robust SNP identification.

NimbleGen Sequence Capture enabled this significant breakthrough in SNP discovery, in particular for species for which breeding efforts were thought to be slowed due to a lack of SNP markers, with the findings of this research presented to the scientific community during the last Plant and Animal Genome Conference in San Diego in January of 2010. Since then, several projects employing this enhanced Sequence Capture technology have been launched by Biogemma for the abovementioned species. The development effort has also proven valuable for other species, as the protocol refinements also appear to make maize sequence capture more attainable. For these new research projects at Biogemma, several candidate genes are now under investigation for better understanding and future improval of several agronomical traits including disease resistance, yield, drought, and nitrogen use efficiency.

"We have been impressed by the speed with which Roche NimbleGen has performed the technical development expected" said Pascual Perez, CEO of Biogemma. "This improved capture technology is now used at Biogemma to optimize our marker development strategy for candidate genes from genomic and functional genomic studies, especially those from our detailed transcriptomic studies. We are now able to saturate genomic regions associated with agronomical traits with novel markers. As a suitable upstream step for current marker and marker assisted selection technologies, this breakthrough is very attractive for Biogemma's shareholders, especially regarding species that haven't been fully sequenced to date."

"We also found improved capture, associated with long read sequencing of the 454 Sequencing System, allowed us to uncover intronic sequences while targeting only exons with an ESTbased design. This provides researchers with access to previously uncharacterized genomic sequences that harbor higher rates of polymorphisms." said Jean-Philippe Pichon, scientist at Biogemma.

'We are excited with this collaboration that extends sequence capture technologies into research on complex plants such as wheat and canola,' said Dr. Frank Pitzer, CEO of Roche NimbleGen. 'This specific study truly shows the flexibility to quickly adapt our NimbleGen Sequence Capture technology to assist in unraveling researchers understanding of the genetic makeup of poorly characterized species and organisms.'

For more information on Roche NimbleGen, visit www.nimblegen.com For more information on Biogemma, visit www.biogemma.com

About Biogemma

Biogemma is a leading agricultural biotech company in Europe involved in Genomics applied to Field Crops. Result of the merger of the biotech activity of three major seed business companies specialized in plant improvement, Vilmorin & Cie (Limagrain Group), Euralis and RAGT and with the help of two financial institutions Sofiproteol and Unigrain with the support of the technical agency Arvalis, the company is developing R&D programs with its partners, in field crops (Corn, Wheat, Sunflower and Rapeseed). Their primary focus is the greatest challenge in agriculture: to explain, explore and enrich the genetic diversity of those crops with the aims of yield improvement, low input of fertilizers, biotic and abiotic stresses tolerances and quality and speciality grain compounds. Biogemma is committed to using an environmentally responsible approach and the latest technology to enable crop breeders to develop innovative plant products.

About Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is a leader in researchfocused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in invitro diagnostics, tissuebased cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80'000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.